Advancing early cancer screening and detection.

Anpac Bio’s Cancer Differentiation Analysis can detect multiple cancers with high sensitivity and specificity.

Anpac Bio uses proprietary algorithms to measure and analyze these signals at multiple biological levels.

Analyzing blood samples with CDA technology.

26 Cancer types detected

Detects the risks of 26 different types of cancer—often identifying cancer at its early stages: Covering 80% of cancer incidences in China from 2013 to 2018

128 Patents granted

128 issued patents granted to date around its Cancer Differentiation Analysis (“CDA”) technology.

Cost Savings

Significant cost advantages compared to other screening technologies

Market Potential

In addition to cancer screening and risk detection, Anpac Bio’s CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.

Results speak. Take a look at our research.

Read the research Anpac Bio scientists presented at the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium, and the Nobel Prize Laureate Summit on Biomedical Sciences.

Matching innovative engineering with clinical research.

We work  with clinicians and scientists to improve our understanding of the biophysics of cancer across the world in the emerging liquid biopsy field.

“game changing”

Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article
©2021 Anpac Bio-Medical Science Co., Ltd.